Early Experience of Rechallenge 177Lu-Psma Radioligand Therapy After an Initial Good Response in Patients With mCRPC

Journal of Nuclear Medicine - China
doi 10.2967/jnumed.118.215715
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Society of Nuclear Medicine

Related search

A Self-Fulfilling Prophecy: Comparing 177Lu-Psma Radioligand Therapy in Taxane Naïve vs Post-Taxane Metastasized Prostate Cancer Patients?

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2019English

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer With 177 Lu-Psma-617

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Tumor Uptake in Glioblastoma Multiforme After IV Injection of [177Lu]Lu-Psma-617

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2020English

Dosimetry Estimate and Initial Clinical Experience With 90y-Psma-617.

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Clinical Outcome of Standardized 177Lu-Psma-617 Therapy in Metastatic Prostate Cancer Patients Receiving 7400 MBq Every 4 Weeks

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2019English

DNA Damage in Blood Lymphocytes in Patients After 177Lu Peptide Receptor Radionuclide Therapy

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2015English

Successful Rechallenge With Gefitinib for an Initial Erlotinib-Responder With Advanced Lung Adenocarcinoma

Tuberculosis and Respiratory Diseases
PulmonaryInfectious DiseasesRespiratory Medicine
2011English

Predictive Factors of Response and Overall Survival in Patients With Castration-Resistant Metastatic Prostate Cancer Undergoing177Lu-Psma Therapy

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Predictors of Long-Term Outcome in Patients With Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy